Patent pools company MPEG LA, LLC has announced an initiative to address what it called “the need for an efficient one-stop license alternative around CRISPR, a breakthrough technology that enables cellular DNA to be edited quickly and inexpensively.”
MPEG LA said some CRISPR patents are currently the subject of an interference proceeding (No. 106048) among various patent holders and applicants before the US Patent and Trademark Office.
“CRISPR’s wide range of potential applications in medicine and agriculture, and the steadily increasing volume of intellectual property in the field, point to the need for a one-stop licensing platform to reduce litigation risk and provide efficiency, transparency and predictability to scientists and businesses worldwide,” said MPEG LA CEO Larry Horn.
“Our worldwide licensing infrastructure, trusted reputation for independence, experience, impartiality and results with patent pools, and relationships with industry and academia, including life sciences, position MPEG LA to deliver a licensing solution for the life sciences market as it did with digital video for the consumer electronics market.”
Kristin Neuman, MPEG LA executive director of biotechnology licensing, said: ““We are mapping the CRISPR Cas-9 patent landscape as a tool for identifying essential patents to be licensed together in a single transaction for various genome engineering applications on a worldwide basis … and will incorporate other genomic engineering technologies as they emerge.”